Redcare Pharmacy: Analysts See 60% Upside, but the Charts Tell a Different Story
Published on 07/25/2026 at 17:22 | Redaktion boerse-global.de
Redcare Pharmacy is celebrating a quarter-century in business this month, yet its share price has little to celebrate. The stock closed the week at €66.05, down 1.42% from seven days earlier, and remains more than 41% below its 52-week high of €112.10. The €70 mark has proven a stubborn ceiling, with a near-3.9% setback on Thursday wiping out the prior week’s gains.
The disconnect between analyst enthusiasm and market reality is striking. Warburg Research recently initiated coverage with a “Buy” rating and a €115 price target, arguing the market underestimates the company’s long-term margin potential — a target implying more than 60% upside from current levels. Barclays followed suit, lifting its price target from €75 to €85. Both firms point to robust operational data: revenue in the first two months of the second quarter grew 20% year-on-year.
The prescription drug business is the standout performer. Redcare’s German Rx segment surged 55% in the first quarter of 2026, prompting management to raise its full-year guidance. The company now expects total revenue growth of between 15% and 17% for 2026. Group revenue in Q1 reached €849.5 million, up 18.4%, while adjusted EBITDA climbed 58% to €14.4 million — though the margin remained wafer-thin at 1.7%. Active customers grew by 1.1 million to 14.2 million over the past year.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
So why isn’t the market buying in? The answer lies partly in the balance sheet: Redcare is still not profitable on a net basis, and the stock remains highly volatile. The share price did stage a recovery from late March, rallying roughly 120%, but that still leaves it far from its highs. The stock’s dual nature — strong operational momentum on one side, persistent skepticism on the other — is likely to dominate the conversation when the company reports half-year results on Wednesday, July 29.
Beyond the numbers, Redcare is building a digital moat. Its “Shop Apotheke” platform ranks as Germany’s most-visited health website, according to Similarweb traffic data. The company also won “App of the Year” in the online pharmacy category, an accolade it attributes to seamless integration of the electronic health card. The e-prescription system is expected to be a key growth driver in coming quarters.
The half-year report will be the critical test. Investors will focus on whether the German Rx segment maintained its first-quarter momentum and whether the adjusted EBITDA margin improved from that slim 1.7% level. A strong showing could finally push the stock through the €70 resistance level. Disappointment, on the other hand, could send it testing support around €60. For now, Redcare remains a story of operational progress that the market has yet to fully price in.
Ad
Redcare Pharmacy Stock: New Analysis - 25 July
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
